Scioto Biosciences

The page says microbiome research is influencing treatment for many diseases and conditions, while few over-the-counter probiotic products have shown significant effects on patient outcomes.

The Gram-positive bacterium Lactobacillus reuteri encounters challenges in the gastrointestinal tract, including low pH, immune system effectors, and competition with other bacteria. These factors can reduce the availability of live bacteria for therapeutic use.

Probiotics reduce the incidence of necrotizing enterocolitis (NEC) when administered at least daily. The company developed a probiotic delivery system that grows probiotics as a biofilm on microspheres, aiming to enhance efficacy with a single treatment.

Scioto Biosciences was founded in 2017 as a partnership between Monon Bioventures and The Research Institute at Nationwide Children’s Hospital. The company works on treatment delivery mechanisms for the microbiome field.

Scioto Biosciences announced a presentation titled “Bugs as Better Drugs: Leveraging Biofilms for Better Live Bacterial Therapeutics” at the Microbiome Movement – Drug Development Summit on June 22 in Boston.

Scioto’s microbial-based intervention is described as improving socialization, communication, and daily living skills.

Scioto Biosciences says gut microbiome ecology may be connected to disorders not previously considered gastrointestinal and that beneficial bacteria may help prevent and treat disease.

Scioto Biosciences, Inc. lists its address as 9800 Crosspoint Blvd, Indianapolis, IN 46256.

Scioto Biosciences is a preclinical-stage biotech company focused on microbiome therapeutics research and discovery.

The website says it collects comment-form data, visitors’ IP addresses, and browser user-agent strings for spam detection.